Human immunodeficiency virus (HIV) phenotype and interleukin-2/ interleukin-10 ratio are associated markers of protection and progression in HIV infection.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Human immunodeficiency virus (HIV) phenotype and interleukin-2/ interleukin-10 ratio are associated markers of protection and progression in HIV infection.

Blood. 1996 Jul 15;88(2):574-9. Unique Identifier : AIDSLINE MED/96289506
Clerici M; Balotta C; Salvaggio A; Riva C; Trabattoni D; Papagno L; Berlusconi A; Rusconi S; Villa ML; Moroni M; Galli M; Cattedra di Immunologia, Universita degli Studi di Milano,; Padiglione L.I.T.A., Ospedale Luigi Sacco, Italy.

Abstract: Human immunodeficiency virus (HIV) isolability, rate of viral replication, HIV phenotype, type 1 and type 2 cytokine production, and CD4 counts were cross sectionally analyzed in 63 HIV seropositive (HIV+) individuals to establish possible correlations between virologic and immunologic markers of protection and progression. We observed that these markers are tightly correlated. Thus, lack or low prevalence of HIV isolability and the presence of nonsyncitium inducing strains are associated with the strongest type 1 cytokine production, the weakest type 2 cytokine production, and highest CD4 counts. Conversely, the isolation of highly replicating, syncitium-inducing HIV strains is associated with the weakest type 1 cytokine production, the strongest type 2 cytokine production, and lowest CD4 counts. Additionally, it was determined that the interleukin (IL)-10/IL-2 ratio best discriminates among different virologic scenarios. These data suggest that the virologic and immunologic correlates of disease protection and progression might be associated variables that define two different subsets of HIV+ individuals and lend support to a viro-immunologic hypothesis of HIV infection.

Keywords: Biological Markers Comorbidity Comparative Study Cytopathogenic Effect, Viral CD4 Lymphocyte Count CD4-Positive T-Lymphocytes/*SECRETION Disease Progression Female Human HIV Infections/BLOOD/*EPIDEMIOLOGY/IMMUNOLOGY/VIROLOGY HIV-1/GENETICS/*ISOLATION & PURIF/PHYSIOLOGY Interleukin-10/*SECRETION Interleukin-2/*SECRETION Italy/EPIDEMIOLOGY Male Phenotype Prospective Studies Risk Factors Sex Behavior Substance Abuse, Intravenous/EPIDEMIOLOGY Support, Non-U.S. Gov't Virus Replication JOURNAL ARTICLE
961130
M96B1876

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .